ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.66 USD 1.14% Market Closed
Market Cap: 281.7m USD
Have any thoughts about
ProQR Therapeutics NV?
Write Note

ProQR Therapeutics NV
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ProQR Therapeutics NV
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
ProQR Therapeutics NV
NASDAQ:PRQR
Net Issuance of Common Stock
€369k
CAGR 3-Years
-85%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Net Issuance of Common Stock
$3.7m
CAGR 3-Years
-9%
CAGR 5-Years
-9%
CAGR 10-Years
-19%
Uniqure NV
NASDAQ:QURE
Net Issuance of Common Stock
$127k
CAGR 3-Years
-85%
CAGR 5-Years
-78%
CAGR 10-Years
-48%
argenx SE
XBRU:ARGX
Net Issuance of Common Stock
$1.3B
CAGR 3-Years
6%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Net Issuance of Common Stock
$487.8m
CAGR 3-Years
36%
CAGR 5-Years
123%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Net Issuance of Common Stock
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ProQR Therapeutics NV
Glance View

Market Cap
281.7m USD
Industry
Biotechnology

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

PRQR Intrinsic Value
2.72 USD
Undervaluation 2%
Intrinsic Value
Price

See Also

What is ProQR Therapeutics NV's Net Issuance of Common Stock?
Net Issuance of Common Stock
369k EUR

Based on the financial report for Sep 30, 2024, ProQR Therapeutics NV's Net Issuance of Common Stock amounts to 369k EUR.

What is ProQR Therapeutics NV's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
6%

Over the last year, the Net Issuance of Common Stock growth was -97%. The average annual Net Issuance of Common Stock growth rates for ProQR Therapeutics NV have been -85% over the past three years , 6% over the past five years .

Back to Top